|Bid||0.206 x 1000|
|Ask||0.259 x 800|
|Day's Range||0.2035 - 0.2115|
|52 Week Range||0.1510 - 9.7500|
|Beta (3Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.50|
SAN DIEGO and PLANEGG-MARTINSRIED, Germany, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology company in Planegg-Martinsried, Germany, today announced that they have entered into a definitive agreement under which Vital Therapies is expected to acquire all of the outstanding shares in Immunic in exchange for newly issued shares of Vital Therapies in an all-stock transaction. The company will focus on advancing Immunic‘s pipeline of novel and potentially transformative treatments for chronic inflammatory and autoimmune diseases.
On a per-share basis, the San Diego-based company said it had a loss of 28 cents. In the final minutes of trading on Wednesday, the company's shares hit 35 cents. A year ago, they were trading at $5.80. ...
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference. Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading.
Every investor in Vital Therapies Inc (NASDAQ:VTL) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tendRead More...
Investors need to pay close attention to Vital Therapies (VTL) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / September 13, 2018 / Bausch Health Companies together with Salix's licensors Cedars-Sinai Medical Center and Alfasigma SpA resolve the outstanding intellectual property litigation ...
The San Diego-based company said it had a loss of 30 cents per share. Vital Therapies shares have increased 45 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares ...
Top-line data from Vital Therapies’ study on the treatment of liver failure is expected to be released in September, Xu said in a Monday note. About 60 percent of sAAH patients are younger patients without renal failure or severe coagulopathy, which are part of the main inclusion criteria for VTL-308.
Investors in Vital Therapies (VTL) need to pay close attention to the stock based on moves in the options market lately.
If you are a shareholder in Vistal Gdynia SA.’s (WSE:VTL), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...